Brief: Tarsus Pharmaceuticals Q2 Net Income USD -33.29 Million Vs. IBES Estimate USD -33.2 Million
08/08/2024 21:05
Aug 08 (Reuters) - Tarsus Pharmaceuticals Q2 basic EPS USD -0.88. * Q2 operating expenses USD 74.115 million
Recent news on Tarsus Pharmaceuticals
See all newsBrief: Lisata Therapeutics Appoints Jeff Farrow To Board Of Directors
Brief: Tarsus Pharmaceuticals Files For Offering Of Up To 2.91 Million Shares Of Common Stock By Selling Stockholders
U.S. RESEARCH ROUNDUP-Argan, Mastec, Oracle
Tarsus Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition (updated)